Highest-materiality recent filing
Ocean Biomedical faces Nasdaq delisting; CFO and director resign
Nasdaq Board declined to review Listing Council decision; final delisting action triggered under Rule 5830 and SEC Rule 12d2-2.
Ocean Biomedical receives Nasdaq delisting affirmation; shares to be suspended
Listing Council affirms Nasdaq's decision to delist Ocean Biomedical securities, effective April 24, 2025.
Elkurt, Inc. terminated all Ocean Biomedical licenses effective July 10, 2025, following an uncured material breach after 30-day cure period expired.
Elkurt, Inc. terminated four Elias Agreements and one Kurtis lab license, plus a RIH license, effective June 9, 2025.
Ocean Biomedical receives Nasdaq delisting notice, plans to appeal; expands into energy and crypto
Nasdaq determined OCEA common stock will be delisted and trading suspended effective April 24, 2025.
CEO Michelle Berrey resigned; also resigned as director along with Jack Elias, Bill Owens, Suren Ajjarapu, Amy Griffith.
Ocean Biomedical lowers note conversion price to $0.01 per share on $400K amount
Conversion price on $400K promissory note reduced irrevocably from $1.50 to $0.01 per share.
Nasdaq notified Ocean Biomedical on March 14, 2025, that stock closed at $0.10 or less for 10 consecutive trading days.
Amy Griffith resigned from the Board effective as of the Annual Meeting.
45,000 shares of Series A preferred issued at $0.01/share; convertible into common at $0.01/share after stockholder approval of reverse split.
Ocean Biomedical amends bylaws to set quorum at 1/3 of outstanding shares
Amendment changes shareholder meeting quorum from previous level to 1/3 of shares outstanding as of record date.
Ocean Biomedical discloses 132,163,312 shares outstanding as of Feb 11, 2025
Issued and outstanding common stock as of February 11, 2025: 132,163,312 shares.
Ocean Biomedical receives Nasdaq delisting notice for failure to hold annual meeting
Nasdaq notified Ocean Biomedical on Jan 7, 2025, that it failed to hold an annual meeting within 12 months of FY2023 end, violating Rule 5620(a).
Ocean Biomedical appoints Berkowitz Pollack Brant as auditor for FY2024
Audit Committee approved engagement of Berkowitz Pollack Brant on Dec 17, 2024.
Ocean Biomedical receives Nasdaq delisting notice for failing MVLS minimum
Nasdaq notified Ocean Biomedical on Dec 5, 2024 that its MVLS was below $35M for 30 consecutive business days.
Ocean Biomedical fails Nasdaq minimum bid price rule; given 180 days to comply
Nasdaq notified Ocean Biomedical of non-compliance with minimum $1 bid price rule on Dec 3, 2024.
Ocean Biomedical dismisses Deloitte & Touche as independent auditor effective Dec. 2, 2024
Dismissed Deloitte & Touche LLP as independent registered public accounting firm effective December 2, 2024.
Ocean Biomedical faces Nasdaq delisting over late Q3 2024 10-Q; hearing Dec 16
Received Nasdaq notice on Nov 18, 2024 for failure to file Form 10-Q for period ended Sep 30, 2024.
CEO Elizabeth Ng takes sabbatical; Director M. Michelle Berrey appointed Interim CEO
Elizabeth Ng notified Board on Oct 23, 2024 of sabbatical for personal reasons.
Ocean Biomedical receives Nasdaq delisting determination for missing filing deadlines
Nasdaq notified company on Oct 16, 2024 that it failed to file Form 10-K for 2023 and Forms 10-Q for Q1 and Q2 2024.
Ocean Biomedical ratifies revised Virion agreement to acquire up to 22% stake for $9M
Board ratified revised agreement dated Nov 2023, received Sep 26, 2024; Ocean to own 22% of Virion fully diluted.
Ocean Biomedical receives Nasdaq notice for late 10-Q filing; must file delinquent reports by Oct 14
Received Nasdaq notice on Aug 19, 2024 for failure to file Q2 2024 Form 10-Q on time.
Ocean Biomedical secures up to $7.675M financing, issues 3.8M shares to settle defaults
Up to $7.675M additional secured notes; first $1.1M tranche used for 2023 audit and quarterly reporting costs.
Ocean Biomedical receives Nasdaq non-compliance notice for late Q1 2024 10-Q filing
Nasdaq notice received May 22, 2024 due to failure to file Form 10-Q for period ended March 31, 2024.
Ocean Biomedical receives Nasdaq deficiency notice for late 10-K filing; must file by Oct 14, 2024
Received Nasdaq notice on April 18, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late filing of Form 10-K for FY2023.
Ocean Biomedical appoints Amy Griffith to board of directors
Amy Griffith appointed director effective March 4, 2024; brings government relations expertise.
Ocean Biomedical appoints Jolie Kahn as CFO effective March 1; predecessor Kalra resigned Jan 30
Gurinder Kalra resigned as CFO effective January 30, 2024 to pursue other interests.
Ocean Biomedical notified by Nasdaq of MVLS below $35M minimum; 180 days to regain compliance
Nasdaq notified Ocean Biomedical on Jan 17, 2024 that its MVLS was below $35M minimum for 30 consecutive business days.
Ocean Biomedical receives Nasdaq bid price deficiency notice; must regain compliance by July 9, 2024
Closing bid price of common stock (OCEA) below $1.00 for 30 consecutive business days through Jan 10, 2024.
Ocean Biomedical receives Nasdaq delinquency notice for late 10-Q; will restate Q1/Q2 2023 results
Nasdaq notified Ocean Biomedical on Nov 22, 2023 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-Q.
Ocean Biomedical restates Q1/Q2 2023 financials over Backstop Agreement classification error
Audit Committee on Nov 10 concluded prior Q1 and Q2 2023 financials should no longer be relied upon.
Ocean Biomedical acquires 50% of Virion Therapeutics for $4.1M cash or 750k shares
Acquired 50% ownership in Virion, a clinical-stage T cell immunotherapy company, for $4.1M cash or 750k shares of common stock.
Non-binding term sheet for up to $10M convertible notes from largest stockholder Poseidon Bio at $10.34 conversion, $11.50 warrants, 1-year maturity.
Ocean Biomedical amends VWAP trigger and reset price in side letter with Polar
Side letter dated October 2, 2023 amends definitions for Polar under Feb 2023 Novation Agreement.
Stockholders approve Nasdaq Proposal for share issuance from convertible notes and warrant
Special meeting held Aug 30, 2023; 25,756,950 shares present (~75.6% of 34,062,724 outstanding).
On April 22, 2025, Jake Kurtis notified the Company of his immediate resignation as a director of the Company to pursue other interests.
Amy Griffith informed the Board of Directors of the Company that she will not be standing for reelection and is resigning from the Board as of the Annual Meeting.
On October 23, 2024, Elizabeth Ng notified the Company’s Board of Directors that she would be taking a sabbatical for personal reasons.
Director, M. Michelle Berrey was appointed to act as Interim Chief Executive Officer, effective immediately.
On March 4, 2024, Amy Griffith has been appointed as a director of Ocean Biomedical, Inc. (the “ Company ”).
On March 1, 2024, the appointment of Jolie Kahn, as Chief Financial Officer of Ocean Biomedical, Inc. (the “Company”) was confirmed.
Ms. Kahn replaces Gurinder Kalra who resigned effective January 30, 2024 to pursue other interests.
On October 6, 2023, Jerome Ringo resigned as a member of Ocean Biomedical’s board of directors.
Max materiality 0.90 · Median 0.70 · Most common event other_material